<?xml version="1.0" encoding="UTF-8"?>
<p id="p0055">Tumor response was assessed through clinical evaluation and imaging studies. Responses were characterized according to the WHO criteria following the third and sixth ICT cycles, 12 weeks following the end of CCRT, and during follow-up visits for disease progression. Post-CCRT monitoring was performed monthly during the first year, bimonthly during the second year, quarterly during the third year, and biannually thereafter until death or data censoring. Adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.</p>
